A recent Indian Phase III randomized open-label study has demonstrated that Sun Pharma’s injectable semaglutide is ...

Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with ...

Emcure slashes semaglutide injection price by 55%, prompting potential moves from Abbott to follow suit in India.

The FDA’s approval of the new weight loss pill Orforglipron marks a shift in the world of obesity treatment. The change may ...

Discover the top 10 weight loss medications of 2026. Explore how advanced GLP-1 therapies and combination drugs are reshaping ...

Novo Nordisk plunges 36% in three months as a weak 2026 outlook, rising competition and pricing pressure cloud near-term ...

The telehealth platform program saves money for some self-pay patients, but experts express concerns about fragmentation of ...

Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity ...

Novo Nordisk remains a compelling investment despite share price weakness, driven by robust innovation and a resilient, ...

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks ...

On Thursday, 2808 stocks advanced, 1539 declined, and 157 remained unchanged on the Bombay Stock Exchange with an ...

Vanda Pharma begins Thetis study, a clinical trial of Nereus for prevention of vomiting induced by GLP-1 receptor agonists: Washington Friday, April 10, 2026, 14:00 Hrs [IST] Vand ...